<DOC>
	<DOCNO>NCT01584297</DOCNO>
	<brief_summary>Our proposal conduct open phase II clinical trial allow u explore activity ketoconazole , inhibitor enzyme CYP17 , ovarian granulosa tumor similar do prostate cancer . The rational base dysregulation FOXL2 mutation present almost granulosa tumor result expression CYP17 appear key development progression disease . This work would represent first attempt address treatment ovarian granulosa cancer molecular solid rational , draw recent identification mutation `` leader '' tumor . If succeed provide widely available therapeutic alternative compare current cancer therapy , low toxicity . In addition would open new line research CYP17 enzyme inhibitor could alter course outcome , usually fatal , advanced stage disease .</brief_summary>
	<brief_title>Ketoconazole Inhibitor Enzyme CYP17 Locally Advanced Disseminated Granulosa Cell Tumour Ovary</brief_title>
	<detailed_description />
	<mesh_term>Granulosa Cell Tumor</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Patients obtain write informed consent . Women ≥18 year old . ECOG ≤ 1 . Histologically confirm carcinoma granulosa cell ovary . Availability sufficient biopsy material confirm diagnosis centralize pathologist determination FOXL2 402C mutation → G ( C134W ) . Metastatic unresectable disease . Imaging measurable disease . Life expectancy ≥ 12 week . Patients adequate hepatic function , define : Serum value AST ALT ≤ 3 x UNL ( except presence metastasis allow value ≤ 5 x UNL ) Total bilirubin ≤ 1.5 x UNL Patients adequate bone marrow function , define : Absolute neutrophil count ≥ 1.5 x 10*9 / L Platelets ≥ 100 x 10*9 / L Hb &gt; 9 g / dL Patients adequate renal function : serum creatinine ≤ 1.5 x UNL . Absence impediment comply study protocol . Women childbearing potential , sexually active , hysterectomy bilateral adnexectomy , follow follow guideline contraception : Negative serum urine pregnancy test within 72 hour start treatment . Use medically accept contraceptive method : 2 month prior study treatment , study 3 month last dose study treatment . Patients another primary tumor 2 year start study drug , exception cervical carcinoma situ adequately treat remove completely basalioma superficial bladder carcinoma . Patients receive radical radiotherapy ≤ 4 week start study treatment recover toxicity radiotherapy . Palliative radiotherapy painful bone lesion allow 14 day start study treatment . Patients heart failure clinically significant heart disease , include follow : History presence uncontrolled severe ventricular arrhythmia . Clinically significant bradycardia rest . LVEF &lt; 45 % assess 2D echocardiogram ( ECHO ) MUGA . Any follow disease within 6 month prior start study drug : Myocardial infarction ( MI ) , severe unstable angina , coronary revascularization , congestive heart failure ( CHF ) , stroke ( CVA ) , transient ischemic attack ( TIA ) . Patients gastrointestinal function failure gastric disease significantly alter ketoconazole absorption , example , severe ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption , extensive resection ( &gt; 1m ) small intestine inability swallow oral medication . The partial total gastrectomy exclusion criterion . Diagnosis infection human immunodeficiency virus ( HIV ) . Pregnant woman nurse . Women childbearing potential use effective contraceptive method . Patients unwilling unable comply protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Granulosa Cell Tumour</keyword>
</DOC>